EPOX	0	4	B-Drug_or_compound
inhibits	5	13	O
angiogenesis	14	26	O
by	27	29	O
degradation	30	41	O
of	42	44	O
Mcl	45	48	B-Gene_or_gene_product
-	48	49	I-Gene_or_gene_product
1	49	50	I-Gene_or_gene_product
through	51	58	O
ERK	59	62	B-Gene_or_gene_product
inactivation	63	75	O
.	75	76	O

PURPOSE	78	85	O
:	85	86	O
Antiangiogenic	87	101	O
therapy	102	109	O
is	110	112	O
considered	113	123	O
as	124	126	O
an	127	129	O
effective	130	139	O
strategy	140	148	O
for	149	152	O
controlling	153	164	O
the	165	168	O
growth	169	175	O
and	176	179	O
metastasis	180	190	O
of	191	193	O
tumors	194	200	B-Pathological_formation
.	200	201	O

Among	202	207	O
a	208	209	O
myriad	210	216	O
of	217	219	O
biological	220	230	O
activities	231	241	O
described	242	251	O
for	252	255	O
xanthone	256	264	B-Drug_or_compound
derivatives	265	276	I-Drug_or_compound
,	276	277	O
the	278	281	O
anticancer	282	292	B-Pathological_formation
activity	293	301	O
is	302	304	O
quite	305	310	O
remarkable	311	321	O
,	321	322	O
but	323	326	O
the	327	330	O
molecular	331	340	O
mechanism	341	350	O
is	351	353	O
not	354	357	O
clearly	358	365	O
resolved	366	374	O
.	374	375	O

In	376	378	O
the	379	382	O
present	383	390	O
study	391	396	O
,	396	397	O
we	398	400	O
investigated	401	413	O
the	414	417	O
antiangiogenic	418	432	O
mechanism	433	442	O
of	443	445	O
3	446	447	B-Drug_or_compound
,	447	448	I-Drug_or_compound
6	448	449	I-Drug_or_compound
-	449	450	I-Drug_or_compound
di	450	452	I-Drug_or_compound
(	452	453	I-Drug_or_compound
2	453	454	I-Drug_or_compound
,	454	455	I-Drug_or_compound
3	455	456	I-Drug_or_compound
-	456	457	I-Drug_or_compound
epoxypropoxy	457	469	I-Drug_or_compound
)	469	470	I-Drug_or_compound
xanthone	470	478	I-Drug_or_compound
(	479	480	O
EPOX	480	484	B-Drug_or_compound
)	484	485	O
,	485	486	O
a	487	488	O
novel	489	494	O
Mcl	495	498	B-Gene_or_gene_product
-	498	499	I-Gene_or_gene_product
1	499	500	I-Gene_or_gene_product
targeting	501	510	O
drug	511	515	O
.	515	516	O

EXPERIMENTAL	517	529	O
DESIGN	530	536	O
:	536	537	O
To	538	540	O
evaluate	541	549	O
the	550	553	O
antiangiogenic	554	568	O
activity	569	577	O
of	578	580	O
EPOX	581	585	B-Drug_or_compound
,	585	586	O
we	587	589	O
did	590	593	O
cell	594	598	B-Cell
viability	599	608	O
,	608	609	O
cell	610	614	B-Cell
cycle	615	620	O
,	620	621	O
tube	622	626	B-Tissue
formation	627	636	O
assay	637	642	O
in	643	645	O
vitro	646	651	O
,	651	652	O
and	653	656	O
Matrigel	657	665	O
plug	666	670	O
assay	671	676	O
in	677	679	O
vivo	680	684	O
.	684	685	O

To	686	688	O
evaluate	689	697	O
the	698	701	O
effect	702	708	O
of	709	711	O
EPOX	712	716	B-Drug_or_compound
on	717	719	O
the	720	723	O
endothelial	724	735	O
signaling	736	745	O
pathway	746	753	O
,	753	754	O
we	755	757	O
did	758	761	O
immunoblotting	762	776	O
,	776	777	O
immunoprecipitation	778	797	O
,	797	798	O
and	799	802	O
immunofluorescence	803	821	O
analysis	822	830	O
.	830	831	O

Intracellular	832	845	O
glutathione	846	857	B-Drug_or_compound
levels	858	864	O
were	865	869	O
determined	870	880	O
with	881	885	O
the	886	889	O
use	890	893	O
of	894	896	O
monochlorobimane	897	913	B-Drug_or_compound
,	913	914	O
a	915	916	O
glutathione	917	928	B-Drug_or_compound
-	928	929	O
specific	929	937	O
probe	938	943	O
.	943	944	O

RESULTS	945	952	O
:	952	953	O
EPOX	954	958	B-Drug_or_compound
induced	959	966	O
endothelial	967	978	B-Cell
cell	979	983	I-Cell
apoptosis	984	993	O
in	994	996	O
association	997	1008	O
with	1009	1013	O
proteasome	1014	1024	O
-	1024	1025	O
dependent	1025	1034	O
Mcl	1035	1038	B-Gene_or_gene_product
-	1038	1039	I-Gene_or_gene_product
1	1039	1040	I-Gene_or_gene_product
degradation	1041	1052	O
.	1052	1053	O

Down	1054	1058	O
-	1058	1059	O
regulation	1059	1069	O
of	1070	1072	O
Mcl	1073	1076	B-Gene_or_gene_product
-	1076	1077	I-Gene_or_gene_product
1	1077	1078	I-Gene_or_gene_product
resulted	1079	1087	O
in	1088	1090	O
an	1091	1093	O
increase	1094	1102	O
in	1103	1105	O
Mcl	1106	1109	B-Gene_or_gene_product
-	1109	1110	I-Gene_or_gene_product
1	1110	1111	I-Gene_or_gene_product
-	1111	1112	O
free	1112	1116	O
Bim	1117	1120	B-Gene_or_gene_product
,	1120	1121	O
activation	1122	1132	O
of	1133	1135	O
Bax	1136	1139	B-Gene_or_gene_product
,	1139	1140	O
and	1141	1144	O
then	1145	1149	O
signaling	1150	1159	O
of	1160	1162	O
mitochondria	1163	1175	O
-	1175	1176	O
mediated	1176	1184	O
apoptosis	1185	1194	O
.	1194	1195	O

Additionally	1196	1208	O
,	1208	1209	O
glutathione	1210	1221	B-Drug_or_compound
depletion	1222	1231	O
and	1232	1235	O
extracellular	1236	1249	B-Gene_or_gene_product
signal	1250	1256	I-Gene_or_gene_product
-	1256	1257	I-Gene_or_gene_product
regulated	1257	1266	I-Gene_or_gene_product
kinase	1267	1273	I-Gene_or_gene_product
(	1274	1275	O
ERK	1275	1278	B-Gene_or_gene_product
)	1278	1279	O
inactivation	1280	1292	O
was	1293	1296	O
observed	1297	1305	O
in	1306	1308	O
EPOX	1309	1313	B-Drug_or_compound
-	1313	1314	O
treated	1314	1321	O
cells	1322	1327	B-Cell
.	1327	1328	O

Glutathione	1329	1340	B-Drug_or_compound
supplementation	1341	1356	O
reversed	1357	1365	O
the	1366	1369	O
inhibitory	1370	1380	O
effects	1381	1388	O
of	1389	1391	O
EPOX	1392	1396	B-Drug_or_compound
on	1397	1399	O
ERK	1400	1403	B-Gene_or_gene_product
,	1403	1404	O
which	1405	1410	O
increases	1411	1420	O
the	1421	1424	O
phosphorylation	1425	1440	O
of	1441	1443	O
Mcl	1444	1447	B-Gene_or_gene_product
-	1447	1448	I-Gene_or_gene_product
1	1448	1449	I-Gene_or_gene_product
at	1450	1452	O
T	1453	1454	B-Protein_domain_or_region
(	1454	1455	I-Protein_domain_or_region
163	1455	1458	I-Protein_domain_or_region
.	1458	1459	O
)	1459	1460	O
Overexpression	1461	1475	O
of	1476	1478	O
mitogen	1479	1486	B-Gene_or_gene_product
-	1486	1487	I-Gene_or_gene_product
activated	1487	1496	I-Gene_or_gene_product
protein	1497	1504	I-Gene_or_gene_product
/	1504	1505	I-Gene_or_gene_product
ERK	1505	1508	I-Gene_or_gene_product
kinase	1509	1515	I-Gene_or_gene_product
(	1516	1517	O
MEK	1517	1520	B-Gene_or_gene_product
)	1520	1521	O
partially	1522	1531	O
reversed	1532	1540	O
the	1541	1544	O
effect	1545	1551	O
of	1552	1554	O
EPOX	1555	1559	B-Drug_or_compound
on	1560	1562	O
Mcl	1563	1566	B-Gene_or_gene_product
-	1566	1567	I-Gene_or_gene_product
1	1567	1568	I-Gene_or_gene_product
dephosphorylation	1569	1586	O
,	1586	1587	O
ubiquitination	1588	1602	O
,	1602	1603	O
and	1604	1607	O
degradation	1608	1619	O
,	1619	1620	O
further	1621	1628	O
implicating	1629	1640	O
ERK	1641	1644	B-Gene_or_gene_product
in	1645	1647	O
the	1648	1651	O
regulation	1652	1662	O
of	1663	1665	O
Mcl	1666	1669	B-Gene_or_gene_product
-	1669	1670	I-Gene_or_gene_product
1	1670	1671	I-Gene_or_gene_product
stability	1672	1681	O
.	1681	1682	O

CONCLUSIONS	1683	1694	O
:	1694	1695	O
This	1696	1700	O
study	1701	1706	O
provides	1707	1715	O
evidence	1716	1724	O
that	1725	1729	O
EPOX	1730	1734	B-Drug_or_compound
induces	1735	1742	O
glutathione	1743	1754	B-Drug_or_compound
depletion	1755	1764	O
,	1764	1765	O
ERK	1766	1769	B-Gene_or_gene_product
inactivation	1770	1782	O
,	1782	1783	O
and	1784	1787	O
Mcl	1788	1791	B-Gene_or_gene_product
-	1791	1792	I-Gene_or_gene_product
1	1792	1793	I-Gene_or_gene_product
degradation	1794	1805	O
on	1806	1808	O
endothelial	1809	1820	B-Cell
cells	1821	1826	I-Cell
,	1826	1827	O
which	1828	1833	O
leads	1834	1839	O
to	1840	1842	O
inhibition	1843	1853	O
of	1854	1856	O
angiogenesis	1857	1869	O
.	1869	1870	O

Our	1871	1874	O
results	1875	1882	O
suggest	1883	1890	O
that	1891	1895	O
EPOX	1896	1900	B-Drug_or_compound
is	1901	1903	O
a	1904	1905	O
novel	1906	1911	O
antiangiogenic	1912	1926	O
agent	1927	1932	O
,	1932	1933	O
making	1934	1940	O
it	1941	1943	O
a	1944	1945	O
promising	1946	1955	O
lead	1956	1960	O
compound	1961	1969	O
for	1970	1973	O
further	1974	1981	O
development	1982	1993	O
in	1994	1996	O
the	1997	2000	O
treatment	2001	2010	O
of	2011	2013	O
angiogenesis	2014	2026	O
-	2026	2027	O
related	2027	2034	O
pathologies	2035	2046	O
.	2046	2047	O

